Terence Flynn
Stock Analyst at Morgan Stanley
(3.87)
# 626
Out of 4,940 analysts
198
Total ratings
59%
Success rate
6.39%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Equal-Weight | $32 → $33 | $24.58 | +34.26% | 18 | Aug 6, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $330 → $333 | $285.09 | +16.81% | 9 | Aug 6, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $255 | $198.64 | +28.37% | 17 | Aug 1, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $171 → $176 | $173.82 | +1.25% | 23 | Jul 17, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $17 → $16 | $9.65 | +65.80% | 5 | Jul 15, 2025 | |
| RPRX Royalty Pharma | Maintains: Overweight | $51 → $54 | $36.19 | +49.21% | 12 | Jul 10, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $99 → $98 | $80.03 | +22.45% | 17 | Jul 10, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $34 | $45.93 | -25.97% | 11 | Jul 10, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $132 → $133 | $109.26 | +21.73% | 4 | Jul 10, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,133 → $1,135 | $635.22 | +78.68% | 20 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $348 → $328 | $300.43 | +9.18% | 10 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $6.59 | +67.05% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $22 | $9.16 | +140.17% | 6 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $10 | $9.01 | +10.99% | 10 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $63 | $13.41 | +369.80% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $55.41 | -42.25% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $10.74 | +2.42% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $17.51 | +573.90% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $4.34 | +729.49% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.42 | +230.58% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $128.00 | +240.63% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $435.00 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.37 | - | 1 | Jul 21, 2017 |
Pfizer
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $32 → $33
Current: $24.58
Upside: +34.26%
Amgen
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $330 → $333
Current: $285.09
Upside: +16.81%
AbbVie
Aug 1, 2025
Maintains: Overweight
Price Target: $250 → $255
Current: $198.64
Upside: +28.37%
Johnson & Johnson
Jul 17, 2025
Maintains: Equal-Weight
Price Target: $171 → $176
Current: $173.82
Upside: +1.25%
Nurix Therapeutics
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $9.65
Upside: +65.80%
Royalty Pharma
Jul 10, 2025
Maintains: Overweight
Price Target: $51 → $54
Current: $36.19
Upside: +49.21%
Merck & Co.
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $99 → $98
Current: $80.03
Upside: +22.45%
Bristol-Myers Squibb Company
Jul 10, 2025
Maintains: Underweight
Price Target: $36 → $34
Current: $45.93
Upside: -25.97%
BioNTech SE
Jul 10, 2025
Maintains: Overweight
Price Target: $132 → $133
Current: $109.26
Upside: +21.73%
Eli Lilly and Company
Jul 10, 2025
Maintains: Overweight
Price Target: $1,133 → $1,135
Current: $635.22
Upside: +78.68%
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $348 → $328
Current: $300.43
Upside: +9.18%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $6.59
Upside: +67.05%
May 9, 2025
Maintains: Overweight
Price Target: $24 → $22
Current: $9.16
Upside: +140.17%
May 5, 2025
Maintains: Equal-Weight
Price Target: $15 → $10
Current: $9.01
Upside: +10.99%
Mar 7, 2025
Maintains: Overweight
Price Target: $69 → $63
Current: $13.41
Upside: +369.80%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $55.41
Upside: -42.25%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $10.74
Upside: +2.42%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $17.51
Upside: +573.90%
Jul 23, 2024
Initiates: Overweight
Price Target: $36
Current: $4.34
Upside: +729.49%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.42
Upside: +230.58%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $128.00
Upside: +240.63%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $435.00
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $8.37
Upside: -